Avantor(US:AVTR)2025-02-07 12:54Financial Highlights - Q4 2024 reported revenue was $169 billion[13], while FY 2024 reported revenue reached $678 billion[13] - Q4 2024 adjusted earnings per share (EPS) stood at $027[13], and FY 2024 adjusted EPS was $099[13] - Q4 2024 free cash flow amounted to $222 million[13], with FY 2024 generating $768 million in free cash flow[13] - Q4 2024 adjusted EBITDA margin was 182%[13], and FY 2024 adjusted EBITDA margin was 177%[13] Segment Performance - Laboratory Solutions reported Q4 2024 revenue of $1126 billion and FY 2024 revenue of $4610 billion[22], with organic growth at -1% and -2% respectively[22] - Bioscience Production reported Q4 2024 revenue of $561 million and FY 2024 revenue of $2174 billion[24], with organic growth at +4% and -3% respectively[24] 2025 Guidance - The company anticipates organic revenue growth of +1% to +3% for FY 2025[26] - The company projects an adjusted EBITDA margin of 18% to 19% for FY 2025[26] - The company expects adjusted EPS to be in the range of $102 to $110 for FY 2025[26] - The company forecasts free cash flow between $650 million and $700 million for FY 2025[26] Clinical Services Divestiture Impact - The divestiture of the Clinical Services business is expected to result in a ~$150 million headwind to reported revenue[31] - The divestiture of the Clinical Services business is expected to result in a ~$50 million headwind to adjusted EBITDA[32]